Fassbender Janelle M, Sherman Mark P, Barr Charles C, Schaal Shlomit
Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky.
Retina. 2016 Oct;36(10):1860-5. doi: 10.1097/IAE.0000000000001030.
To analyze and compare the effects of three common treatment modalities for a thick subfoveal hemorrhage due to exudative age-related macular degeneration on final visual acuity and the size of the final subretinal scar.
Retrospective case series.
Single-site, tertiary referral center.
Thirty-nine patients with exudative age-related macular degeneration and acute SMH greater than 250 μm.
Patients received vitrectomy with a subretinal tissue plasminogen activator (tPA) injection, pneumatic displacement (PD) with intravitreal tPA, or PD without tPA within 2 weeks of presentation.
Functional outcome was determined by Snellen visual acuity. Anatomical outcome was determined as the final disciform scar size.
Treatment groups did not differ in age, sex, initial visual acuity, the initial area of the thick subfoveal hemorrhage, follow-up duration, lens status, duration of exudative age-related macular degeneration, previous intravitreal bevacizumab injections, or time from last given injection to the acute thick subfoveal hemorrhage. Final visual acuity improved significantly in both the vitrectomy and subretinal tPA injection group (P < 0.001), and the intravitreal tPA injection group (P = 0.002) but not with PD alone. Patients treated with subretinal tPA achieved 40% ± 54% reduction in final scar area, in contrast to 27% ± 35% decrease in patients treated with intravitreal tPA (P = 0.001).
Treatment with tPA improves the functional and anatomical outcomes in patients with thick subfoveal hemorrhage due to subfoveal choroidal neovascular membrane secondary to exudative age-related macular degeneration and was superior to PD without tPA. Vitrectomy with subretinal tPA injection reduced the final disciform scar compared with PD with or without intravitreal tPA.
分析和比较三种常见治疗方式对渗出性年龄相关性黄斑变性所致的黄斑中心凹下厚出血在最终视力及最终视网膜下瘢痕大小方面的影响。
回顾性病例系列研究。
单中心三级转诊中心。
39例渗出性年龄相关性黄斑变性且急性黄斑下出血大于250μm的患者。
患者在就诊后2周内接受玻璃体切除术联合视网膜下组织纤溶酶原激活剂(tPA)注射、玻璃体腔内tPA注射的气体置换术(PD)或不使用tPA的PD。
功能转归通过Snellen视力测定。解剖学转归通过最终盘状瘢痕大小测定。
治疗组在年龄、性别、初始视力、黄斑中心凹下厚出血的初始面积、随访时间、晶状体状态、渗出性年龄相关性黄斑变性病程、既往玻璃体腔内贝伐单抗注射情况或从最后一次注射到急性黄斑中心凹下厚出血的时间方面无差异。玻璃体切除术联合视网膜下tPA注射组(P<0.001)和玻璃体腔内tPA注射组(P=0.002)的最终视力显著改善,但单纯PD组未改善。视网膜下tPA治疗的患者最终瘢痕面积减少40%±54%,相比之下,玻璃体腔内tPA治疗的患者减少27%±35%(P=0.001)。
tPA治疗可改善渗出性年龄相关性黄斑变性继发的黄斑中心凹下脉络膜新生血管膜所致的黄斑中心凹下厚出血患者的功能和解剖学转归,且优于不使用tPA的PD。与使用或不使用玻璃体腔内tPA的PD相比,玻璃体切除术联合视网膜下tPA注射可减少最终盘状瘢痕。